Shenzhen Yinghe Brain Science Co., Ltd, a China-based neurotechnology firm, has reportedly raised over RMB 100 million (USD 14.7 million) in an angel financing round. The round was led by Bioching Capital and Lilly Asia Ventures, with participation from Shenzhen New Industries Biomedical Engineering Co., Ltd, Xi’an Xijiao 1896 Science and Technology Innovation Investment Partnership, and existing investors. This funding will support the company’s ongoing development and expansion in the field of neuroregulation and brain-computer interface technology.
Company Background and Focus
Yinghe Brain Science, a spin-off of Enlight Medical, specializes in the development of next-generation neuroregulation and brain-computer interface technology and products. The company has multiple products in various stages of development, including animal experiments and clinical trials, positioning it as a leader in the emerging field of neurotechnology.
Future Outlook
With this significant funding, Yinghe Brain Science is poised to accelerate its R&D efforts and bring innovative neuroregulation solutions to market. The company’s focus on advanced brain-computer interfaces and neuroregulation technology aligns with growing global interest in these fields, offering potential benefits for patients with neurological conditions.-Fineline Info & Tech
